Navigation Links
CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
Date:7/21/2008

September meeting to focus on use of Zevalin as consolidation therapy after

remission induction in previously untreated patients with follicular

lymphoma

SEATTLE, July 22 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the Company has scheduled a meeting with the U.S. Food and Drug Administration (FDA) in September to discuss the possibility of filing a supplemental Biologics License Application (sBLA) for use of Zevalin(R) ([90Y]-ibritumomab tiuxetan) as consolidation therapy after remission induction in previously untreated patients with follicular non-Hodgkin's lymphoma. The basis for the filing would be data from the First-line Indolent Trial that CTI recently gained access to through an agreement with Bayer Schering Pharma.

"We are pleased to have scheduled a meeting with the FDA to discuss a label expansion for Zevalin which could broaden its availability to patients," said James A. Bianco, M.D., President and CEO of Cell Therapeutics. "We continue to make progress with Zevalin on multiple fronts with clarity on reimbursement rates, deployment of our national sales team and now the opportunity to meet with the FDA to discuss possibly expanding the label for Zevalin."

About the Phase III First-line Indolent (FIT) Trial

The multinational, randomized phase III First-line Indolent Trial (FIT) evaluated the benefit and safety of a single infusion of Zevalin in patients with CD20-positive follicular non-Hodgkin's lymphoma who had achieved a partial response or a complete response after receiving standard first-line chemotherapy regimens. The FIT trial results were presented in one oral and two poster presentations at the American Society of Hematology (ASH) conference in December 2007. The FIT trial demonstrated that when used as a first-line consolidation therapy for patients with follicular non-Hodgkin's lymphoma, Zevalin significantly impro
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Public Forum to Discuss Addiction as a Treatable Disease and Highlight National Alcohol and Drug Addiction Recovery Month
2. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Threshold to Host Conference Call to Discuss Results From Clinical Presentations at European Cancer Conference (ECCO)
5. Most Women With HIV and Their Health Care Providers Have Not Discussed How HIV Might Affect Them Differently Than Men
6. APIC Conference to Discuss MRSA Elimination
7. ReachMD Broadcasts First-of-its-Kind Physician Peer-Peer Discussion on ENHANCE Trial
8. Mayo Clinic Proceedings Contributors Discuss Impact of Donor Organ Allocation System
9. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
10. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
11. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)... 20 Reportlinker.com announces tha... catalogue. ,, Pipettes & Pipettors - A Gl...linker.com/p0164373/Pipettes--Pipettors---A-Global...;utm_medium=pr&utm_campaign=prnewswire ,,... part of any research laboratory. Large-scale appl...
(Date:11/20/2009)... 20 Reportlinker.com announces tha... catalogue. ,, Global Markets for Assisted Rep...inker.com/p0164742/Global-Markets-for-Assisted-Rep...amp;utm_medium=pr&utm_campaign=prnewswire ,...s the U.S., 15 Countries in Europe and Japan. This...
(Date:11/20/2009)... Biotel Inc. (OTC Bullet...arter ended September 30, 2009 with net earnings o...s of $3,263,000. This compares to net earnings of... of $3,168,000 for the first quarter of last year....otel President and CEO Steve Springrose said: "Bio...
Breaking Medicine Technology:Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 2Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 3Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 4Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 5Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 6Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 7Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 8Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 9Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 10Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 11Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 12Reportlinker Adds Global Markets for Assisted Reproductive Devices 2009 2Biotel Announced Profitable First Quarter Ended September 30, 2009 2Good Nutrition Can Fuel the Whole Family Even the Four Legged Members 51449 1Good Nutrition Can Fuel the Whole Family Even the Four Legged Members 51449 2Good Nutrition Can Fuel the Whole Family Even the Four Legged Members 51449 3Schizophrenia Drug Got Bad Rap 51447 1Schizophrenia Drug Got Bad Rap 51447 2InteKrin Therapeutics Announces Appointment of Geoffrey M Parker as Chief Business Officer 51443 1InteKrin Therapeutics Announces Appointment of Geoffrey M Parker as Chief Business Officer 51443 2
... Prostate Cancer Awareness Month, MIAMI and PALM ... Awareness Month, and the CyberKnife Centers of Mi...y to treat prostate cancer,without surgery and lon...is,the most common form of cancer affecting men in... M.D., says, "for many cases,that are diagnosed ea...
...all Scheduled for Today - Tuesday, September 2, 20...Time, MOUNTAIN VIEW, Calif., Sept. 2 Alexza,Phar... positive results from,its first Phase 3 clinical ...renic patients with acute agitation. Both the 5 mg...t of the trial, which was a statistically,signific...
Other Medicine Technology:Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients 2Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients 3Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients 4Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients 5Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients 6Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients 7Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients 8Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients 9
(Date:11/21/2009)... New Haven Dental Group merge....D.S of Branford, CT. , (...roup, comprised of partners Dr. David Gibson, Dr. ...orrester has just merged their growing practice wi...n., , ,When Dr. Pickman decided he wanted to retir...
(Date:11/20/2009)... , Pioneering Neurologist Closer to Understand...v. 20 Dr. Jeremy Schmah...hool and neurologist at the Massachusetts General ...ented his laboratory,s research on the new field o... MINDlink Foundation. ,, Dr. Schmahmann is an a...
(Date:11/20/2009)... , WASHINGTON, Nov. 20 /PRNewswire-USNewswir...ing senators to modify health care reform legislat...e regarding a health insurance individual coverage... enforceable mandate will minimize adverse selecti... rules prescribed by the bill. ,, "The individu...
(Date:11/20/2009)... , QUINCY, Mass., Nov. 20 Foll...ermarket Company removed from sale Shedd,s Country...Rice and Shedd,s Country Crock ® Side Dishes ...ite allergen. ,, The following code dates and ...174; Side Dishes DELUXE Cheddar Broccoli Rice 21 o...
(Date:11/20/2009)... , MADISON, N.J., Nov. 20 /PRNewswire-First...enza virus may have peaked in late October, but th...ource of illness in all age groups, including the ...stics Incorporated (NYSE: DGX ), the world,s lea...nd services. ,, In its most recent Quest Diagn...
Breaking Medicine News(10 mins):Health News:New Haven Dental Group Expands Their Vision 2Health News:MINDlink Foundation Launches to Connect the Cerebellum to Cures 2Health News:Actuaries to Senate: Strengthen Individual Mandate 2Health News:Stop & Shop Alerts Customers to Voluntary Recall by Unilever 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 3
...r Institute of Medical Sciences (MIMS) is planning...a. // MIMS, run by a group of non-resident I...ouncil (GCC) countries, has already acquired four ...an Azad Moopen told the newspaper that the promote...
...ears of an avian flu outbreak has caused Australia...asks. // Pandemic risk committees in compainie...ompanies such as Bluescope Steel and Telstra while...t of an outbreak have been included in the prepara...
...ysis that compares two common inhalers for patient...ease //(COPD) finds that one reduces respiratory-r...t the other -- which is prescribed in the majority...nd that common bronchodilators known as anticholin...
... of Missouri-Columbia researchers have found that ...rgo treatment, combating the chronic disease //by ...estimated 1.3 million new cases of cancer were dia...oduced side effects such as weight gain or loss, f...
...to a study which was published in the Internationa... protected people against billiary tract cancer //... Billiary tract cancers are very rare but are fat...ent for billiary tract cancer live over five years...
...rchers report that thousands of genes behave diffe...omething never detected to this degree.// The stud...s males and females differently, and why the gende...iseases," explained Xia Yang, Ph.D., first author ...
Other Medicine News:Health News:Australian Businesses Prepare for Outbreak of Bird Flu 2Health News:COPD Patients Using Beta-agonist Inhalers Are at Risk 2Health News:Same Genes Act Differently in Males and Females 2Health News:Same Genes Act Differently in Males and Females 3
Pediatric One-Piece Cystoscopes
Continuous Flow Cystoscopes
Prolieve™ Thermodilatation System
The Prostatron® System
Medicine Products: